? Having built out a commercial footprint in the US and led the launch of Bavencio for Merck KGaA, David Trexler is taking up a new role as president of German biotech Morphosys? US subsidiary. Following a dual listing on the Nasdaq $MOR last year, MorphoSys is plotting a swift rollout for MOR208 once the FDA approves its use in diffuse large B cell lymphoma ? now with a guiding hand from Trexler, who?s also worked sales and marketing for Eisai?s US oncology unit.
? Michelle Berrey ? the woman who replaced Chimerix CEO Kenneth Moch in 2014 a